Beijing Center

After purchasing 53.8% equilities of DHY&CO., LTD, Yifan formally enters into the field of macromolecular innovative biologics. Yifan owns one Dikine TM: Dimeric Cytokine Platform, in which several macromolecular biologics have been in international clinical II and III stages, and Yifan has been the first domestic company whose innovative biologics enters into Phase II and Phase III in America. All solutions of products under research and the listed products are produced by Evive BioPharmaceutical(Beijing)Co., Ltd..

Evive Biotech is a global biologics company with A...